Chronic Lymphocytic Leukemia Excellence Forum

Chronic Lymphocytic Leukemia

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Conference Coverage

Treatment Strategies for Patients With Double Refractory Chronic Lymphocytic Leukemia

02/27/2024

Featuring Neil E. Kay, MD

At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Neil E. Kay, MD, discusses the pathobiology and management of double refractory CLL.

At the Lymphoma, Leukemia &...

02/27/2024

Lymphoma, Leukemia & Myeloma Network

Videos

Chronic Lymphocytic Leukemia Pathways in Practice at Rocky Mountain Cancer Centers

02/05/2024

Featuring John Burke, MD

John Burke, MD, discusses the current treatment landscape for chronic lymphocytic leukemia and how his center ensures a comprehensive approach to patient care.

John Burke, MD, discusses the...

02/05/2024

Journal of Clinical Pathways

Recent Developments and Emerging Therapies in Chronic Lymphocytic Leukemia

01/10/2024

Featuring Ian Flinn, MD

Ian Flinn, MD, talks about recent developments in chronic lymphocytic leukemia treatment, emerging therapies that show promise, and how Tennessee Oncology’s new research center will improve access to clinical trials for more patients.

Ian Flinn, MD, talks about...

01/10/2024

Journal of Clinical Pathways

Videos

The Impact of Racial and Socioeconomic Disparities in Patients With Chronic Lymphocytic Leukemia

01/02/2024

Featuring Ira Zackon, MD

Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients with Chronic...

Ira Zackon, MD, New York...

01/02/2024

Journal of Clinical Pathways

Conference Coverage

Trends in the Use of Bruton Tyrosine Kinase Inhibitors and B-cell 2 Inhibitors for Treating CLL in Community Oncology Settings

11/29/2023

Edited by Grace Taylor

Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.

Jing-Zhou Hou, MD, and...

11/29/2023

Journal of Clinical Pathways

News

Racial Differences in Ibrutinib Treatment Outcomes in Patients With CLL: A Real-World Analysis

11/28/2023

Edited by Emry Lloyd

Study on real-world data on patients with chronic lymphocytic leukemia investigated the outcomes for both Black and White patients.

Study on real-world data on...

11/28/2023

Journal of Clinical Pathways

Videos

How Cone Health Uses Clinical Pathways to Deliver Optimal Patient Care

09/28/2023

Featuring Andre Harvin, PharmD

Featuring Andre Harvin, PharmD ...

In this interview, Andre Harvin, PharmD, chief pharmacy officer and vice president of Pharmacy Services at Cone Health, breaks down how their cancer center develops and utilizes clinical pathways and discusses how their team stays up to date...

In this interview, Andre Harvin,...

09/28/2023

Journal of Clinical Pathways

News

Analysis of the Impact Bruton Tyrosine Kinase Inhibitor Discontinuation Has After First- or Second-Line Therapy

08/22/2023

Emry Lloyd

Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.

Researchers studied data on the...

08/22/2023

Journal of Clinical Pathways

Videos

A Real-World Analysis of Factors Leading to Racial Disparities in the Overall Survival of Patients with CLL

06/22/2023

Featuring Adam Kittai, MD

Adam Kittai, MD, The Ohio State University Comprehensive Cancer Center, discusses his study on the causes of racial disparities in the overall survival of patients with chronic lymphocytic leukemia.

Adam Kittai, MD, The Ohio State...

06/22/2023

Journal of Clinical Pathways

Videos

Analyzing Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia

05/22/2023

Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, discusses his study that analyzed trends in...

Edward R. Scheffer Cliff, MBBS,...

05/22/2023

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Recent Stories

Videos

Chronic Lymphocytic Leukemia Treatment Updates

07/31/2024

Farrukh T. Awan , MD;

Farrukh Awan, MD, discusses some of the most important advancements in chronic lymphocytic leukemia (CLL) treatment over the past 10 years.

Farrukh Awan, MD, discusses some...

07/31/2024

Journal of Clinical Pathways

Videos

Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024

07/18/2024

Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).

Steve Kalloger, MSc, discusses...

07/18/2024

Journal of Clinical Pathways

Conference Coverage

Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL

06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...

At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...

At the 65th ASH Annual Meeting,...

06/26/2024

Oncology

Interview

Oncology Drug Shortages: Causes and Solutions

05/28/2024

Ryan Motte, PharmD, CSP, Shields Health Solutions

Ryan Motte, PharmD, CSP, Shields Hea...

Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.

Ryan Motte, PharmD, discusses...

05/28/2024

Journal of Clinical Pathways

Interview

CLL Treatment Updates and the Integration of AI into CLL Clinical Trials

05/20/2024

Shaalan Beg, MD, MBA, FASCO

Shaalan Beg, MD, MBA, FASCO, describes some of the recent advancements in the treatment of chronic lymphocytic leukemia (CLL).

Shaalan Beg, MD, MBA, FASCO,...

05/20/2024

Journal of Clinical Pathways

Chronic Lymphocytic Leukemia Excellence Forum

Current Issue

Special Reports

Subscribe

Recent Stories

Specialties

Events

Year Round Education

HMP Global Products